Navigation Links
Court Preliminarily Deems Millennium Laboratories' Press Release 'Misleading'

BALTIMORE, June 14, 2012 /PRNewswire/ -- Ameritox(SM), the nation's leader in pain medication monitoring, announced today that the Baltimore, MD, Federal Court issued a Preliminary Injunction order against Millennium Laboratories for misleading statements contained within a Millennium Laboratories press release.  The Preliminary Injunction confirms the court's initial concerns about the Millennium Laboratories press release that led to its issuance of the Temporary Restraining Order on Wednesday, June 13, and moves from a temporary restriction to enjoining Millennium Laboratories' action regarding the press release. Following is the language directly from the Preliminary Injunction issued by the Court on Thursday, June 14, 2012:

"On June 13, 2012, Millennium and Ameritox entered into, and the Court approved, a Consent Order that concluded the above-captioned Lanham Act case. Docket No. 321. Later the same day, Millennium issued a press release (the "Press Release") concerning the litigation and the Consent Order. Docket No. 306-1. Upon motion by Ameritox, the Court granted a Temporary Restraining Order requiring, inter alia, that Millennium take down the Press Release from its web site, and enjoining Millennium's sales representatives from using the Press Release in sales presentations or communications. Docket No. 329.

On June 14, 2012, the Court reviewed written submissions from both sides and convened a sealed hearing. For reasons that the Court stated on the record, the undersigned granted Ameritox's motion to convert the Temporary Restraining Order to a Preliminary Injunction (Docket No. 324).1 This order effectuates that ruling.

To set the record straight, the Court will publish a brief opinion stating clearly the advertisements that were accused under the Lanham Act, the grounds upon which the advertisements were accused, the evidentiary limitations imposed by the Court, the recommendations of the advisory jury, and the rulings of the Court. The Court will issue this opinion as soon as practicable.

Until the Court can write the opinion and review it with counsel, the interests of justice require that Millennium be enjoined from distributing the Press Release or using it in sales presentations. Hence, the Court is issuing this preliminary injunction.

As the Court explained during today's hearing, a preliminary injunction is warranted under the standard articulated in Winter v. Natural Resources Defense Council, Inc., 555 U.S. 7, 20 (2008). Moreover, the Court has inherent authority to enjoin misleading statements concerning litigation before it. See Am. Sci. & Eng'g, Inc. v. Autoclear, LLC, 606 F. Supp. 2d 617, 626 (E.D. Va. 2008) (orderingremoval of a press release that contained misleading statements about the court's rulings).2

The Court is not enjoining all communication by the parties regarding this litigation, but only the Press Release that the Court has, on the basis of the record before it, preliminarily deemed to be misleading. The injunction is, therefore, appropriately tailored. See Cornwell v. Sachs, 99 F. Supp. 2d 695, 708 (E.D.Va. 2000).

For the foregoing reasons, it is this 14th Day of June, 2012, hereby ORDERED as follows:

1. The Temporary Restraining Order issued on June 13, 2012 (Docket No. 329) is VACATED;

2. Millennium shall remove the Press Release from its web site; and

3. Pending further Order of Court, Millennium is preliminarily enjoined from using the Press Release in sales presentations or communications or otherwise disseminating it to the public.

About Ameritox

Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx Guardian(SM) – with Rx Guardian CD(SM), the only pain medication screening with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at, on Twitter @Ameritox, or on Facebook at




Lon Wagner
Director of Communications

SOURCE Ameritox Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Surgical Corp. Develops Online Sterilization Resource Center
2. Millennium Surgical Corp. Announces Sales Figures, Growth
3. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
4. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
5. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
6. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
7. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
8. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
9. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
10. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
11. Generex Announces Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Smart and Beddit Classic sleep tracking systems. The new app features a more intuitive ... see and understand how well you slept. The SleepScore is created by a proprietary ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
Breaking Medicine News(10 mins):